Eli Lilly and Company (LLY)

Acerca de Eli Lilly and Company

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Al 3 de noviembre de 2026, la acción de Eli Lilly and Company (LLY) subió a $1,434.20, un alza de 1.65% (+$23.22) frente al cierre anterior. En la sesión, las acciones han operado entre $1,393.61 y $1,436.21. Eso ubica a LLY cerca del máximo de su rango de 52 semanas, de $850.51 a $1,449.68. Eli Lilly and Company opera en el sector de pharmaceutical preparations y tiene una capitalización de mercado de aproximadamente $1.26 billones, con cerca de 279.4 mil acciones negociadas.

Últimas noticias de LLY

• What Could Derail Bristol Myers Squibb Stock?trefis.com· 3 nov, 9:12 a.m. ET
• Lilly’s R&D whirlwind — what the large pharma has taken in and what it’s droppedpharmavoice.com· 3 nov, 8:48 a.m. ET
• Eli Lilly Just Delivered Another Monster Quarter. But There’s More to This Story Than Weight-Loss Drugs247wallst.com· 3 nov, 8:03 a.m. ET
• Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on ItYahoo Finance· 3 nov, 8:00 a.m. ET
• How to Invest in the Rise of China’s Biotech: Buy U.S. Drug StocksYahoo Finance· 3 nov, 6:15 a.m. ET
• LLY Stock Up Almost 10% After a Robust Q3: Time to Buy, Sell or Hold?Yahoo Finance· 3 nov, 6:11 a.m. ET
• Eli Lilly Just Gained 22% in a Month: Take Profits, or Buy More?tikr.com· 3 nov, 6:08 a.m. ETNVO
• ETFs Bought $147.9 Million of Eli Lilly (LLY) on Oct. 30Yahoo Finance· 3 nov, 6:01 a.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de LLY en un solo lugar? Crea una cuenta gratis →

• $PDSB $SPRB $LLY $SLS $IBRX Top 5 Biotech Stocks of 2027. https://x.com/JSipp712/status/2116148386529489027?a=23bLF-zzgOKNdWAl6w0&s=20

  @Simon_Phoenix· 3 nov, 9:43 a.m. ET· Alcista

• $LLY the bigger they are…the harder they….uhh I forget

  @SimmyTradesStocks· 3 nov, 9:33 a.m. ET· Bajista

• $ABCL $MRNA $REGN $SLS $LLY As I was listening to past conferences this snippet from JP Morgan held on Jan 15, 2025 stands out for me. Hansen’s closing remarks talk about the next 5-10 years. He’s not thinking about the next quarter or trying to appeal to the short term. He’s …

  @Stocktradesmoon· 3 nov, 9:13 a.m. ET· Alcista

• $ABCL $MRNA $REGN $SLS $LLY $ABCL 👀🔥 There is zero fundamental reason to support ABCL falling in price. If anything, the stock is too cheap right now. People don’t understand the sheer magnitude of what this company will do, and sadly those people will be left behind… I’m ju…

  @Stocktradesmoon· 3 nov, 8:29 a.m. ET· Alcista

• JPMorgan🏁 $TRXB and said--We are initiating coverage of TRexBio (TRXB) with an OW rating and a Dec- 2027 PT of $20. [ $JNJ $LLY [ABBV SNY - REGN PFE CRVS QTTB MANE NKTR CLDX Dren Bio, ALYS Pharma, Legacy Healthcare, Reistone, Suzhou, EVMN KYMR BCRX ACRX]] JPMorgan went on to …

  @Quantumup· 3 nov, 7:18 a.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →